Cullinan Therapeutics, Inc. (CGEM) stock
Close on Nov 11, 2026Market cap $730.43MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $730.43M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -24.07%
Fundamentals
- Net income
- -$219.88M
- Free cash flow
- -$175.80M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $11.23
- Open
- $11.34
- Day's range
- $11.15 – $11.68
- Volume
- 985,830
- Average volume (20 days)
- 834,528
- Index membership
- Russell 2000 (since Mar 2021), Russell 3000 (since Feb 2021)
- Beta (5 years)
- 0.87
- 52-week range
- $7.25 – $23.19
- RSI (14 days)
- 34.0
- Volatility (1 year)
- 82.0%
- Relative volume
- 1.16×
- WACC
- 9.2%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CGEM | S&P 500 | Difference | CGEM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.9% | -2.4% | −24.5 pts | ||
| 3 months | -42.2% | -1.2% | −41.0 pts | ||
| Year to date | +9.7% | +12.3% | −2.6 pts | ||
| 1 year | +45.5% | +12.4% | +33.1 pts | ||
| 3 years | +24.9% | +78.8% | −53.9 pts | +7.7% | +21.4% |
| 5 years | -48.7% | +75.2% | −123.9 pts | -12.5% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cullinan Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Update
- Update
About Cullinan Therapeutics
Biological Products, (No Diagnostic Substances)
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for autoimmune diseases and cancer. Its research and development efforts center on T cell engagers and targeted therapies. The company's pipeline includes CLN-978, a bispecific T cell engager being evaluated for autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's disease. It is also developing velinotamig for autoimmune conditions, as well as CLN-049 for acute myeloid leukemia and myelodysplastic syndrome. In addition, the firm collaborates on zipalertinib, an oral targeted inhibitor for non-small cell lung cancer. Its prospective customers are patients with autoimmune diseases and cancers.
Company profile, executives and historyCullinan Therapeutics stock: common questions
What is Cullinan Therapeutics's stock price?
CGEM closed at $11.35 on Nov 11, 2026, up 1.07% on the day. Over the past 52 weeks it traded between $7.25 and $23.19.
What is Cullinan Therapeutics's market cap?
Cullinan Therapeutics was worth $730.43M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Cullinan Therapeutics pay a dividend?
No. Cullinan Therapeutics has not paid a cash dividend over the last twelve months.
When does Cullinan Therapeutics report earnings next?
Cullinan Therapeutics is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CGEM stock performed over the past year?
Including dividends, CGEM returned +45.5% over the past year, against +12.4% for the S&P 500.
How many CGEM shares are sold short?
8M shares were sold short at the latest FINRA report, 13.83% of the float, or 13.3 days of average trading volume.
Who are Cullinan Therapeutics's competitors?
Companies most similar to Cullinan Therapeutics by business, industry and size include TCRX, ALLO, ESLA, CVM, IPSC.
See a number that looks wrong?